Castration Resistant Prostate Cancer clinical trials

Explore recruiting castration resistant prostate cancer clinical trials.

Recruiting castration resistant prostate cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Castration Resistant Prostate Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 1/2 First-Time-in-Human, open-label, multicenter, dose escalation and dose optimization study of GSK5471713 in adult participants with metastatic castration resistant prostate cancer (mCRPC).

Netherlands, France

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

CARLHA-2_AN OPEN LABEL, RANDOMIZED, PHASE III STUDY EVALUATING THE EFFICACY OF ACOMBINATION OF APALUTAMIDE WITH RADIOTHERAPY AND LHRH AGONIST IN HIGH-RISK POST-PROSTATECTOMY BIOCHEMICALLY RELAPSED PROSTATE CANCER PATIENTS

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

(21140 ARANOTE) A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide in addition to androgen deprivation therapy (ADT) versus placebo plus ADT in men with metastatic hormone-sensitive prostate cancer (mHSPC).

Spain, Latvia, Lithuania

Therapeutic confirmatory (Phase III) EU CTIS Study details

Efficacy and safety of cannabidiol for pain relief of patients with end-stage metastatic castration resistant prostate cancer - a randomised double-blinded placebo-controlled phase II trial (ProCan)

Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase 2 INSPIRE trial: Ipilimumab with Nivolumab in molecular-selected patients with castration-resistant prostate cancer

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours (TROPION-PanTumor03)

Poland, France, Italy, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Castration Resistant Prostate Cancer trials by city

Castration Resistant Prostate Cancer in Toronto Castration Resistant Prostate Cancer in Vancouver Castration Resistant Prostate Cancer in Montreal Castration Resistant Prostate Cancer in Calgary Castration Resistant Prostate Cancer in Edmonton Castration Resistant Prostate Cancer in Ottawa Castration Resistant Prostate Cancer in Winnipeg Castration Resistant Prostate Cancer in Quebec City Castration Resistant Prostate Cancer in Hamilton Castration Resistant Prostate Cancer in Kitchener Castration Resistant Prostate Cancer in London Castration Resistant Prostate Cancer in Halifax Castration Resistant Prostate Cancer in New York Castration Resistant Prostate Cancer in Los Angeles Castration Resistant Prostate Cancer in Chicago Castration Resistant Prostate Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease